• Omeros Corp., of Seattle, said it closed the registered direct offering of 3.9 million shares of common stock priced at $4.14 per share, raising net proceeds of about $16.1 million. Funds will be used for general corporate purposes, including expenses related to the potential commercialization of OMS302 for intraocular lens replacement, as well as for R&D expenses such as funding planned clinical trials for its OMS103HP, PDE10, MASP-2 and PDE7 programs. Proceeds also may be used to fund preclinical studies, capital expenditures, working capital and to advance the firm's potential products toward commercialization.
To read more on related topics, click on one of the words below.